Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: GlobeNewswire
PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be participating at upcoming conferences taking place during the week of the JP Morgan Healthcare Conference 2025. “I am looking forward to these opportunities to discuss the incredible progress we have made in 2024 with our Alzheimer’s and dementia with Lewy body (DLB) programs,” stated Ms. Ricciardi. “We capped off 2024 with positive topline results from our Phase 2 SHIMMER study in patients with DLB and are looking forward to presenting these findings at the International Lewy Body Dementia Conference at the end of January in Amsterdam. We are preparing now for our end-of-Phase 2 meeting with the FDA to review results from our SHINE study in mild-to-moderate Alzheimer’s disease, an important regulatory milestone. In addition, we
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesGlobeNewswire
- Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceGlobeNewswire
- Cognition Therapeutics (NASDAQ:CGTX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
CGTX
Earnings
- 5/7/25 - Miss
CGTX
Sec Filings
- 12/18/25 - Form 8-K
- 12/18/25 - Form S-3
- 11/6/25 - Form 10-Q
- CGTX's page on the SEC website